- Indivior PLC (NASDAQ:INDV) said the FDA informed it that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
- Indivior said that it will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
- Source: Press Release
Indivior said FDA has delayed approval of SUBLOCADE label changes (NASDAQ:INDV)
By Press Room
